Crescent Capital Partners has acquired Nucleus Network Ltd from Baker IDI Heart and Diabetes Institute.

The sale will help Baker focus on boosting biotechnology and medical research by generating more funds, and will also enable it to operate on cardiovascular diseases and diabetes.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Baker Institute will continue to hold up to 20% stake in Nucleus Network.

Crescent Captial company is a private equity firm, while Nucleus Network company is a research institute. Both companies are based in Australia.

“Baker Institute will continue to hold up to 20% stake in Nucleus Network.”

Ipca Pharmaceuticals Inc and Onyx Scientific Ltd have acquired a 100% share capital of Pisgah Labs Inc for $9.65m in cash.

Based in the US, Pisgah Labs is a contract manufacturer and developer of active pharmaceutical ingredients (APIs). It will continue to operate from its North Carolina manufacturing facility under the Pisgah trade name following the acquisition.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The acquisition will result in merging Onyx Scientific and Pisgah’s capabilities in chemistry services effectively with IPCA Labs capabilities to support phase II to commercial-scale programmes.

It will also help in enabling IPCA Labs to produce small volume APls for the US market.

Based in the US, Ipca Pharmaceuticals Inc is a wholly owned subsidiary of IPCA Laboratories. Onyx Scientific Ltd is a step-down subsidiary of IPCA Laboratories based in the UK.